$38.32
2.22% yesterday
Nasdaq, Jan 06, 10:00 pm CET
ISIN
US8808811074
Symbol
TERN

Terns Pharmaceuticals Inc Stock price

$38.32
-1.91 4.75% 1M
+34.32 858.00% 6M
-2.08 5.15% YTD
+32.61 571.10% 1Y
+29.19 319.72% 3Y
+21.32 125.41% 5Y
+21.32 125.41% 10Y
+21.32 125.41% 20Y
Nasdaq, Closing price Tue, Jan 06 2026
-0.87 2.22%
ISIN
US8808811074
Symbol
TERN
Industry

Key metrics

Basic
Market capitalization
$4.2b
Enterprise Value
$3.9b
Net debt
positive
Cash
$295.6m
Shares outstanding
87.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
14.7
Financial Health
Equity Ratio
95.0%
Return on Equity
-25.7%
ROCE
-37.9%
ROIC
-5,105.6%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-108.8m | $-112.7m
EBIT
$-108.5m | $-114.7m
Net Income
$-94.4m | $-96.9m
Free Cash Flow
$-78.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-9.0% | -11.0%
EBIT
-7.9% | -12.6%
Net Income
-6.8% | -9.0%
Free Cash Flow
-5.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.0
FCF per Share
$-0.9
Short interest
11.7%
Employees
59
Rev per Employee
$0.0
Show more

Is Terns Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,084 stocks worldwide.

Terns Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Terns Pharmaceuticals Inc forecast:

16x Buy
94%
1x Hold
6%

Analyst Opinions

17 Analysts have issued a Terns Pharmaceuticals Inc forecast:

Buy
94%
Hold
6%

Financial data from Terns Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 31 31
3% 3%
-
- Research and Development Expense 77 77
11% 11%
-
-109 -109
9% 9%
-
- Depreciation and Amortization -0.28 -0.28
137% 137%
-
EBIT (Operating Income) EBIT -108 -108
8% 8%
-
Net Profit -94 -94
7% 7%
-

In millions USD.

Don't miss a Thing! We will send you all news about Terns Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Terns Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
4 days ago
FOSTER CITY, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of January 1, 2026 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended.
Neutral
GlobeNewsWire
26 days ago
FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the closing of its previously announced underwritten public offering of 18,687,500 shares of its common stock, including 2,437,500 shares sold pursuant to the underwriters' exercise in full of their option to purchase ad...
Neutral
GlobeNewsWire
28 days ago
FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the pricing of its upsized underwritten public offering of 16,250,000 shares of its common stock at a public offering price of $40.00 per share, before underwriting discounts and commissions. The gross proceeds from the ...
More Terns Pharmaceuticals Inc News

Company Profile

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Head office United States
CEO Amy Burroughs
Employees 59
Founded 2017
Website ternspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today